3-(13-hydroxy-tridecyl)-4,4-dimethyl-2-cyclohexen-1-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-(13-hydroxy-tridecyl)-4,4-dimethyl-2-cyclohexen-1-one
• 英文别名: 3-(13-hydroxytridecyl)-4,4-dimethyl-2-cyclohexen-1-one；3-(13-Hydroxytridecyl)-4,4-dimethylcyclohex-2-en-1-one
• 化学式: C₂₁H₃₈O₂
• 分子量: 322.532
• InChiKey: DIMCJRWLDZRVIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  23
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4,4-二甲基-2-环己基-1-酮 在 盐酸 、 正丁基锂 、 三苯基甲烷 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 六甲基磷酰三胺 、 氯仿 、 水 、 丙酮 、 苯 为溶剂， 反应 55.0h， 生成 3-(13-hydroxy-tridecyl)-4,4-dimethyl-2-cyclohexen-1-one
  参考文献：
  名称：

  Cyclohexenonic Long-Chain Fatty Alcohols as Neuronal Growth Stimulators

  摘要：

  神经营养因子在神经元的发育和维持中起着重要作用，因此为治疗神经退行性疾病提供了合适的疗法。然而，由于存在一系列技术和生物学上的缺点，它们在临床应用中遇到了问题。在提出的不同克服这些困难的策略中，寻找具有神经营养潜力的非肽类物质正取得令人鼓舞的成果。本文将展示该领域的主要发现，特别关注环己烯型长链脂肪醇，这是一个促进神经元存活和神经突延伸的新型化合物家族。

  DOI：

  10.3390/51201439

文献信息

• Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder
  申请人：Satoh Keisuke

  公开号：US20080312336A1

  公开（公告）日：2008-12-18

  The present invention provides preventive and/or therapeutic agents for either one, or both, of a diabetic vascular disorder and a diabetic respiratory disorder comprising, as an active ingredient, a cyclohexenone long chain alcohol compound represented by the following formula (1): [wherein R 1 , R 2 , and R 3 each represent a hydrogen atom or a methyl group, and X represents a linear or branched C10-C28 alkylene or alkenylene group]. Since the cyclohexenone long chain alcohol of formula (1) improves diabetic vascular smooth muscle contraction and bronchial smooth muscle contraction, it is useful as a preventive and/or therapeutic agent for a diabetic vascular disorder or a respiratory disorder.

  本发明提供了预防和/或治疗糖尿病血管疾病和糖尿病呼吸道疾病的预防和/或治疗剂，其活性成分为以下式（1）所表示的环己烯酮长链醇化合物： [其中R1、R2和R3分别表示氢原子或甲基基团，X表示线性或支链C10-C28烷基或烯基基团]。 由于式（1）中的环己烯酮长链醇改善了糖尿病血管平滑肌收缩和支气管平滑肌收缩，因此它可用作糖尿病血管疾病或呼吸道疾病的预防和/或治疗剂。
• Therapeutic Agent for Sensory Abnormality
  申请人：Shiomi Hirohito

  公开号：US20090069442A1

  公开（公告）日：2009-03-12

  The present invention provides therapeutic agents for sensory disorders represented by the following formula (1): [wherein R 1 , R 2 , and R 3 each represent a hydrogen atom or a methyl group, and X represents a linear or branched C10-C28 alkylene or alkenylene group]. The cyclohexenone long chain alcohol of the present invention improves hyperalgesia or hypoalgesia, and thus is useful as therapeutic agents for sensory disorders. Sensory disorders that can be prevented or treated by the present invention include chronic intractable pain, neurogenic pain, reduction of pain threshold caused by nerve injuries, hypesthesia or hyperesthesia caused by diabetes and nerve injuries, and the like.

  本发明提供了治疗感觉障碍的治疗剂，其由以下式子（1）所代表的环己烯酮长链醇构成：[其中R1，R2和R3分别代表氢原子或甲基基团，X代表线性或支链C10-C28烷基或烯基基团]。本发明的环己烯酮长链醇改善了高敏性或低敏性，因此可用作治疗感觉障碍的治疗剂。本发明可以预防或治疗的感觉障碍包括慢性顽固性疼痛、神经性疼痛、由神经损伤引起的疼痛阈值降低、由糖尿病和神经损伤引起的感觉减退或过敏等。
• THERAPEUTIC AGENT FOR SENSORY ABNORMALITY
  申请人：Meiji Dairies Corporation

  公开号：EP1839653A1

  公开（公告）日：2007-10-03

  The present invention provides therapeutic agents for sensory disorders represented by the following formula (1): [wherein R1, R2, and R3 each represent a hydrogen atom or a methyl group, and X represents a linear or branched C10-C28 alkylene or alkenylene group]. The cyclohexenone long chain alcohol of the present invention improves hyperalgesia or hypoalgesia, and thus is useful as therapeutic agents for sensory disorders. Sensory disorders that can be prevented or treated by the present invention include chronic intractable pain, neurogenic pain, reduction of pain threshold caused by nerve injuries, hypesthesia or hyperesthesia caused by diabetes and nerve injuries, and the like.

  本发明提供了下式（1）所代表的感官失调治疗剂： [其中 R1、R2 和 R3 分别代表氢原子或甲基，X 代表线性或支链 C10-C28 烯基或烯基]。 本发明的环己烯酮长链醇可改善痛觉减退或痛觉不全，因此可用作感觉障碍的治疗剂。本发明可预防或治疗的感觉障碍包括慢性顽固性疼痛、神经源性疼痛、神经损伤引起的痛阈降低、糖尿病和神经损伤引起的低痛觉或高痛觉等。
• Cyclohexenone derivative for treating or preventing hypesthesia or hyperesthesia caused by diabetes
  申请人：Meiji Dairies Corporation

  公开号：EP2196200A1

  公开（公告）日：2010-06-16

  The present invention provides therapeutic agents for sensory disorders represented by the following formula (I): [wherein R1, R2, and R3 each represent a hydrogen atom or a methyl group, and X represents a linear or branched C10-C28 alkylene or alkenylene group]. The cyclohexenone long chain alcohol of the present invention improves hyperalgesia or hypoalgesia, and thus is useful as therapeutic agents for sensory disorders. Sensory disorders that can be prevented or treated by the present invention include chronic intractable pain, neurogenic pain, reduction of pain threshold caused by nerve injuries, hypesthesia or hyperesthesia caused by diabetes and nerve injuries, and the like.

  本发明提供了下式（I）所代表的感官失调治疗剂： [其中 R1、R2 和 R3 分别代表氢原子或甲基，X 代表线性或支链 C10-C28 烯基或烯基]。 本发明的环己烯酮长链醇可改善痛觉减退或痛觉不全，因此可用作感觉障碍的治疗剂。本发明可预防或治疗的感觉障碍包括慢性顽固性疼痛、神经源性疼痛、神经损伤引起的痛阈降低、糖尿病和神经损伤引起的低痛觉或高痛觉等。
• Effect of cyclohexenonic long chain fatty alcohols on neurite outgrowth. Study on structure-activity relationship
  作者：Céline Girlanda-Junges、Florence Keyling-Bilger、Gaby Schmitt、Bang Luu

  DOI：10.1016/s0040-4020(98)00406-2

  日期：1998.7

  Four series of long chain fatty alcohols bearing a cyclohexenone moiety in addition to a omega-alkanol side chain were synthesized using "Umpolung" reactivity strategy. Their effect on neurite outgrowth was evaluated by means of fetal rat neurons in culture. The length of the omega-hydroxy side chain is a crucial factor for biological activity. (C) 1998 Elsevier Science Ltd. All rights reserved.